Cited by 516Adipokines, Inflammation, and Metabolic DiseasesRegulation of Appetite and ObesityCardiovascular Disease and Adiposity

Leptin resistance

Open access
Martin, Seth S., Qasim, Atif, Reilly, Muredach P.·2008·Journal of the American College of Cardiology

Abstract

Leptin is an adipocyte-derived hormone and cytokine that regulates energy balance through a wide range of functions, including several that are important to cardiovascular health. Increased circulating leptin, a marker of leptin resistance, is common in obesity and independently associated with insulin resistance and cardiovascular disease (CVD) in humans. The mechanisms of leptin resistance include genetic mutation, leptin self-regulation, limited tissue access, and cellular or circulating molecular regulation. Evidence suggests that central leptin resistance causes obesity and that obesity-induced leptin resistance injures numerous peripheral tissues, including liver, pancreas, platelets, vasculature, and myocardium. This metabolic- and inflammatory-mediated injury may result from either resistance to leptin's action in selective tissues, or excess leptin action from adiposity-associated hyperleptinemia. In this sense, the term "leptin resistance" encompasses a complex pathophysiological phenomenon. The leptin axis has functional interactions with elements of metabolism, such as insulin, and inflammation, including mediators of innate immunity, such as interleukin-6. Leptin is even purported to physically interact with C-reactive protein, resulting in leptin resistance, which is particularly intriguing, given C-reactive protein's well-studied relationship to cardiovascular disease. Given that plasma levels of leptin and inflammatory markers are correlated and also predict cardiovascular risk, it is conceivable that part of this risk may be mediated through leptin resistance-related insulin resistance, chronic inflammation, type II diabetes, hypertension, atherothrombosis, and myocardial injury. Leptin resistance and its interactions with metabolic and inflammatory factors, therefore, represent potential novel diagnostic and therapeutic targets in obesity-related cardiovascular disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2008.05.060

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The adipocyte acts as an endocrine organ and plays a substantial role in the pathogenesis and complications of obesity.

    “The adipocyte acts as an endocrine organ, and plays a substantial role in the pathogenesis and complications of obesity (1,10).”

    From Obesity and Cardiovascular Disease (2009) · cites this paper as [10]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 137 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Martin, S. S., Qasim, A., & Reilly, M. P.
Affiliations
University of Pennsylvania (US)
Corresponding author
Reilly, Muredach P.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2008-10
Volume
52
Issue
15
Pages
1201-1210
ISSN
0735-1097 (ISSN-L)
OpenAlex
W102714011
Cited by
516
References
137
Citations by year
2026: 14 · 2025: 22 · 2024: 19 · 2023: 21 · 2022: 18 · 2021: 35 · 2020: 32 · 2019: 23 · 2018: 26 · 2017: 34 · 2016: 31 · 2015: 37 · 2014: 34 · 2013: 38 · 2012: 31
FWCI
3.60
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK071224)
Topics
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
leptin resistance, leptin, obesity, cardiovascular disease, insulin resistance, hyperleptinemia, chronic inflammation, interleukin-6, C-reactive protein, type 2 diabetes, hypertension, atherothrombosis, myocardial injury, energy balance, leptin signaling
MeSH terms
Animals, Cardiovascular Diseases, Humans, Inflammation, Obesity, Leptin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review